This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Formoterol HFA-MDI
Description: Formoterol HFA-MDI is a formulation of the long-acting beta-agonist formoterol (the active ingredient of Foradil), that will be used in MDIs. The HFA refers to the hydrofluoroalkane propellant, which is replacing chlorofluorocarbon (CFC) propellants due to environmental concerns.
SkyePharma and Vectura
In March 2016, the Boards of Skyepharma and Vectura announced that they had reached agreement regarding the terms of a recommended merger (the Merger), to be implemented by way of a court sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the Scheme), pursuant to which Vectura will acquire the entire issued and to be issued ordinary share capital of Skyepharma.
Further to the announcement made by the Boards of Skyepharma and Vectura on June 10, 2016, that the Scheme has now become effective in accordance with its terms, Vectura announces that 260,800,264 New Vectura Shares being issued pursuant to the Scheme were admitted to listing on the premium listing segment of the Official List and were admitted to trading on the London Stock Exchange's main market for listed securities, in each case with effect from 8.00 a.m on June 10, 2016.
Therefore, Vectura has 671,521,605 issued ordinary shares each with equal voting...See full deal structure in Biomedtracker
Formoterol HFA-MDI News
Additional information available to subscribers only: